MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-08

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with Alzheimer's disease and with early onset of symptoms (\<65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground. In addition, some MA-J have an atypical phenotype indicating focal brain damage, although they have the same pathological lesions: amyloid deposits and tau protein deposition (DNF). This is the case of posterior cortical atrophy (PCA) characterized by complex visual disturbances and atrophy affecting the more posterior regions of the brain. Based on the clinical profile of PCA patients, a more refined anatomo-clinical classification was proposed, distinguishing a rather "ventral" form and a rather "dorsal" form. The recent arrival of tau-specific PET tracers now makes it possible to evaluate in vivo fibrillary neurodegeneration (FND), which is well correlated with the severity of cognitive disorders. Advances in MRI have shown that each neurodegenerative syndrome targets a large-scale neural network, which in turn shows a vulnerability for a specific biological disease. In the case of AD, the reason for such a difference in cognitive and anatomical impairment between patients with diffuse involvement and others with more focal involvement is not known. One possible explanation is the existence, in focal forms, of neuronal mechanisms that oppose vulnerability. These mechanisms may correspond to the so-called "resilience" phenomenon, defined as resistance to a neuropathological process by the ability to optimize cognitive performance via the efficient recruitment of neural networks. The mechanisms underlying resilience in neurodegeneration are unknown. Their identification is very important for the management and treatment of AD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multi-modal Neuroimaging in Alzheimer's Disease

NCT01554202

Alzheimer's Disease

UNKNOWN NA

Neuro Imaging and Multimodal Alzheimer's Disease

NCT02839187

Alzheimer Disease

COMPLETED NA

Multi-modal Neuroimaging in Alzheimer's Disease

NCT01638949

Alzheimer's Disease

COMPLETED NA

Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging

NCT01815112

Alzheimer Disease Mild Cognitive Impairment Vascular Dementia

TERMINATED NA

FluoroAv45 Imaging Research-in Alzheimer's Disease

NCT01325259

Alzheimer's Disease Mild Cognitive Impairment

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Working hypotheses We hypothesize that "focal" patients (PCA) versus "diffuse" patients (AD-Y) have (i) less severe white matter involvement; (ii) effective reorganization of the functional brain networks; iii) pathologically, a different topography and lesion load.

This project has no redundancy with the work already done in our team and in other teams at the international level.

Expected benefits This study will highlight the neural mechanisms underlying resiliency in a group of AD patients who, although having the same disease, present with a very different clinical and cognitive profile. Demonstration of these specific mechanisms of resilience in the diseased brain is essential to better understand the pathophysiological processes of AD. We consider that the pharmacological approach and the functional reeducation to this disease depend essentially on a better knowledge of both the topographic distribution of the underlying histopathology (in particular, the tau protein), and the response capacity from the brain to these lesions (state of connection of networks, functional reorganization). In addition, when treatments for AD are available, a precise definition of phenotypic variants will be essential for the selection of patients for these therapies and for therapeutic follow-up. In the longer term, resilient neural circuits could be modulated and strengthened through transcranial stimulation. Indeed, promising results have been obtained showing that these techniques can improve the performance of altered cognitive functions in patients with dementia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease, Early Onset Posterior Cortical Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Nombre de participants 45 sujets répartis dans 3 groupes:

1. Groupe MA-J (Maladie d'Alzheimer précoce)= 15 patients avec un diagnostic de MA-J
2. Groupe ACP (Atrophie Corticale Posterieure)= 15 patients avec un diagnostic d'ACP
3. Groupe sujets contrôles= 15 sujets contrôles

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Alzheimer (<65 years) (AD-Y)

15 patients with a diagnostic of MA-J

Group Type EXPERIMENTAL

TEP/IRM

Intervention Type DEVICE

All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.

Patients with posterior Cortical Atrophy (PCA)

15 patients with a diagnostic of PCA

Group Type EXPERIMENTAL

TEP/IRM

Intervention Type DEVICE

All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.

Control

15 controls

Group Type ACTIVE_COMPARATOR

TEP/IRM

Intervention Type DEVICE

All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TEP/IRM

All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. For all subjects:

* Affiliation to a social security insurance or beneficiary
* Informed consent form signed by the participant or his / her legal representative
* Participants aged 40 to 80 years.
2. Selection of AD-Y group

\- In vivo proof of Alzheimer's pathology:
* Determination of specific proteins on the cerebrospinal fluid (CSF, a routine care procedure). The values considered pathological (AD) are Aβ1-42 peptide \<500 (μg / ml), and / or tau protein\> 450 and phosphorylated tau protein\> 60, IATI index \<1, tau / Aβ protein ratios \> 1.23 as well as phosphorylated tau protein / Aβ1-42\> 0.211.
* And / or a positive PET-amyloid imaging test.
* Early-onset episodic memory deficit (\<65 years), progressive onset with evidence of hippocampal amnesic syndrome at neuropsychological assessment.

In memory tests, the amnesic hippocampal syndrome is defined by: a deficit of the free recall despite a reinforced encoding, an effectiveness of the indexing or an impairment of the recognition capabilities, the presence of intrusions. The presence during the tests of false memories spontaneous (intrusions) or provoked (false recognitions) is also very contributive to the definition of amnesic syndrome of the hippocampal type.
3. PCA group selection

Patients with a clinical and cognitive profile suggestive of PCA, characterized by:
* an in vivo proof of the Alzheimer pathology (see selection of the AD-Y group)
* a specific impairment of neuro-visual abilities, in the absence of major disorders of episodic memory (hippocampal) and executive functions.

Two possible variants:
* occipito-temporal variant: visuo-perceptive deficit in the foreground, early onset and progressive worsening; lack of visual identification of objects, symbols, words or faces;
* biparietal variant: visuospatial deficit in the foreground, early settlement and progressive worsening; Gerstmann syndrome; Balint syndrome; gestural apraxia; visual-spatial neglect.
4. Selection of the control subjects group

* Normal neurological and neuropsychological examinations.
* Control subjects will be matched in age to patients.

* Medical history of torsade de pointe or risk of torsade de pointes
* Patient treated with drugs known to lengthen QT (see www.crediblemeds.org)
* Contraindication to radiopharmaceutical injection:

For precautions of safety of use of the radiopharmaceutical, a blood sample allowing to check the renal and hepatic functions will be realized before imagery. The delay between the sampling and the neuroimaging visit is left to the investigator's discretion based on the patient's biological results. In particular, the glomerular filtration rate will be calculated from the results obtained.

In the event of renal insufficiency (GFR 30mL / min / 1.73m2), hepatic insufficiency or any other biological anomaly of grade 3 or higher detected during these analyzes, the participant will not be able to carry out PET imaging. In this case, the results of the analyzes will be sent to the doctor indicated by the participant. This evaluation, which involves a determination of serum creatinine, is part of the standard routine biological assessment performed in the context of cognitive disorders

Inability to provide informed consent by participant or legal representative:
* Patient deprived of liberty by decision of justice or not benefiting from social cover.
* Person in the process of participating in another therapeutic research or in a period of exclusion from another research.
* Participants with a contraindication to MRI: pacemaker or cardiac defibrillator, implanted equipment activated by an electrical, magnetic or mechanical system, haemostatic clips of intracerebral aneurysms or carotid arteries , carriers of orthopedic implants.
* Contraindication to radiopharmaceutical injection: known hypersensitivity to the active substance or to any of the excipients, renal impairment (GFR 30mL / min / 1.73m2), hepatic insufficiency or any other biological abnormality of grade 3 or higher
* Person suffering from claustrophobia.
* Pregnancy (for women of childbearing age, a urine pregnancy test will be performed on the day of the inclusion visit and the PET-MRI examination).
* Any symptoms or biological values suggestive of a systemic disorder (renal, hepatic, cardiovascular, pulmonary) or any other medical conditions that could interfere with the interpretation of test results or compromise the health of patients.
* Person subject to a legal safeguard.

* Sudden appearance of cognitive deficits.
* Gait disturbances, convulsions, major behavior modification.
* Focal alterations to neurological examination, extrapyramidal signs, hallucinations, fluctuations. cognitive.
* Psychiatric, cerebrovascular, metabolic, inflammatory pathology.

* Pathological neurological examination
* History of neurological disease (in particular ischemic stroke or neurodegenerative disease) or psychiatric illness (particularly severe depression, psychosis, or bipolar illness still requiring drug treatment at the time of inclusion)
* Physical affection that is serious or can interfere with cognitive functions.

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes